Skip to main content

Global Point of Care (PoC) Imaging Devices Market to Reach $19.84 Billion by 2030

 According to a new market intelligence report by BIS Research titled “Global Point of Care imaging devices Market – Analysis & Forecast 2020-2030”, The global point of care (PoC) imaging devices market was valued at $8.66 billion in 2019 and is expected to reach $19.84 billion by the end of 2030, clocking a CAGR of 8.70%, during the forecast period.

BIS Research Report -  https://bisresearch.com/industry-report/point-of-care-imaging-devices-market.html

The diagnostic imaging technology ecosystem is facing significant changes in its market dynamics as new methodologies, technologies, and practices are currently being introduced in the market. The ecosystems are going through a period of amendments, driven by increasing demand for emerging technologies and its adoption in the healthcare sector. Several other factors ranging rising aging population to secure economic development in the emerging nations too are driving the growth of the PoC imaging devices market.

Request for a Sample:  https://bisresearch.com/requestsample?id=952&type=download

Some of the key drivers for the growth of the point of care (PoC) imaging devices market include growing need for more patient convenience, increased healthcare spending by countries to ramp up their healthcare infrastructure, and higher preference due to economic consideration.

PoC imaging devices are aimed at ensuring minimum inconvenience for patients. Thus, point of care imaging devices can be used at a patient’s bedside. The places include hospitals, ambulatory surgical centers, and also their homes. The use of handheld devices allows the scan to be performed at the patients’ homes, reducing or eliminating the need for hospital visits and is particularly useful for elderly patients. Furthermore, the use of handheld PoC enabled devices is now more relevant due to the ongoing COVID-19 pandemic.

The PoC imaging devices market comprises some of the leading players in the medical imaging ecosystem. These include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Shimadzu Corporation, Fujifilm Holdings Corporation, Samsung Electronics Co., Ltd., Canon Inc., and Digirad Corporation, among others. Additionally, there has been an increasing number of start-ups in the market which are gaining prominence or are expected to launch their product soon, including Butterfly Network, Inc., Hyperfine Research, and Perimeter Medical Imaging, among others.

 

The answers to the following key questions can be derived from this report:

·         What are the key regulations governing the Point-of-Care (PoC) Imaging devices market?

·         What are the key technological developments on which the current industry leaders are spending a major share of their R&D investment?

·         How is the role of PoC imaging devices expected to evolve in the future?

·         What level of impact will the COVID-19 crisis have on the market in terms of change in demand and the functioning of the supply chain?

·         Which leading players are holding a major share of the PoC imaging devices market?

·         What are the current business models and key strategies adopted by leading players, and how likely are those models to persist in future market scenarios?

Comments

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: •     Industry Analysis    ...